COVID-19 Information
ASN
Resources
Vaccines/
Therapeutics
CDC
Links
CMS
Updates
Other
Orgs
Publications
on COVID-19
To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.
learn more1401 H St, NW, Ste 900, Washington, DC 20005
email@asn-online.org
202-640-4660
ASN
Resources
Vaccines/
Therapeutics
CDC
Links
CMS
Updates
Other
Orgs
Publications
on COVID-19
Vaccine/Therapeutics Spotlight |
CDC: Noravax |
Food and Drug Administration: |
ASPR: |
---|---|---|
The CDC has endorsed that the Novavax vaccine be used as an option for adults ages 18 years and older. The Novavax COVID-19 vaccine is the first COVID-19 protein subunit vaccine recommended for use in the United States. Having multiple types of vaccines offers more options and flexibility for patients and vaccine providers. | The U.S. Food and Drug Administration (FDA) recently updated the fact sheet for Emergency Use Authorization (EUA) for Paxlovid (14 April 2022). They have also developed a Paxlovid patient eligibility screening checklist to aid in support for clinical decision making for prescribers as well as managing potential drug interactions. | The national map below displays locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under FDA EUA authority. The long-acting antibody combination, Evusheld; the monoclonal antibody treatment, bebtelovimab; as well as the oral antiviral therapies Lagevrio, Paxlovid, and Renal Paxlovid. |
Noravax Overview & Safety |
Paxlovid Fact Sheet |
Therapeutics Locator |
Recommendation Statement |
Patient Screening |
Therapeutics Page |